Novel ADC Insights to Inform Your Biomarker & CDx Strategy

  • New research on how an antibody-drug conjugate (ADC) can bypass internalization, leading to the bystander effect
  • How the tumor microenvironment and immune interactions could influence patient stratification and ADC-immunotherapy combo strategies
  • How AI spatial proteomics and IHC, H&E-based quantitative biomarker scoring can give deeper insights into the MOA and efficacy of ADCs